Avacta Group PLC AVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 45.30
- Day Range
- GBX 44.00–45.50
- 52-Week Range
- GBX 43.00–166.98
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 16.16 Bil
- Volume/Avg
- 2.9 Mil / 3.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 113
- Website
- https://www.avacta.com
Comparables
Valuation
|
Metric
|
AVCT
|
BVXP
|
ZURA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 28.17 | — |
Price/Book Value | 5.39 | 20.20 | 2.66 |
Price/Sales | 7.34 | 17.27 | — |
Price/Cash Flow | — | 25.71 | — |
Price/Earnings
AVCT
BVXP
ZURA
Financial Strength
|
Metric
|
AVCT
|
BVXP
|
ZURA
|
|---|---|---|---|
Quick Ratio | 0.66 | 6.69 | 4.92 |
Current Ratio | 0.71 | 7.04 | 4.97 |
Interest Coverage | −3.70 | — | — |
Quick Ratio
AVCT
BVXP
ZURA
Profitability
|
Metric
|
AVCT
|
BVXP
|
ZURA
|
|---|---|---|---|
Return on Assets (Normalized) | −41.74% | 68.76% | −71.08% |
Return on Equity (Normalized) | −122.29% | 77.21% | −139.85% |
Return on Invested Capital (Normalized) | −53.10% | 76.10% | −99.89% |
Return on Assets
AVCT
BVXP
ZURA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rvwyzvlcjk | Gmkfk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mffvzrqm | Tjsvs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vywvhmqx | Pbhpzc | $97.8 Bil | |
MRNA
| Moderna Inc | Bpdhkzpg | Tftl | $38.8 Bil | |
ARGX
| argenx SE ADR | Knnmptng | Sjh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ypnckpmv | Pjqk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jdtygml | Rtmvrs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jjpzctxy | Cvjfsmq | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lbdxkzvf | Sjxjz | $12.5 Bil | |
INCY
| Incyte Corp | Frgxdhxx | Dspryln | $11.5 Bil |